CHF Solutions to Exhibit at The International Society for Heart and Lung Transplantation 2019 Annual Meeting and Scientific S...
March 28 2019 - 8:30AM
CHF Solutions (Nasdaq: CHFS), today announced it will be exhibiting
at the 2019 Annual Meeting and Scientific Sessions of the
International Society for Heart and Lung Transplantation (ISHLT) on
April 3-6, 2019 at the Lowes Meeting Complex in Orlando, Fla.
The company can be found on the exhibition floor at booth #408.
“We continue to expand our reach within the cardiovascular
community in order to demonstrate the value of ultrafiltration
therapy in post-operative cardiac surgery. We recently
announced the additional focus of using the Aquadex Flex Flow
system post-surgery, and we believe that the ISHLT is an excellent
opportunity to increase awareness,” said John Erb, chairman and CEO
of CHF Solutions.
About the ISHLT
The International Society for Heart and Lung Transplantation
(ISHLT) is a not-for-profit, multidisciplinary, professional
organization dedicated to improving the care of patients with
advanced heart or lung disease through transplantation, mechanical
support and innovative therapies via research, education and
advocacy. The purposes of the Society are: promoting the
association of persons interested in the fields of heart and lung
transplantation, end-stage heart and lung disease and related
sciences; encouraging and stimulating basic and clinical research
in heart and lung transplantation and end-stage heart and lung
disease, and promoting new therapeutic strategies; holding
scientific meetings featuring presentations and discussions
relevant to heart and lung transplantation and the treatment of
end-stage heart and lung disease; sponsoring a scientific journal
for the publication of manuscripts related to these disciplines;
maintaining an international registry for heart and lung
transplantation; awarding research grants and establishing
endowments for the study of heart and lung transplantation and
end-stage heart and lung disease, when funds are available and
without jeopardizing the financial well-being of the organization;
and sponsoring and conducting educational activities and providing
educational resources, which promote expert development and improve
standards of care in advanced heart and lung disease, heart and
lung transplantation, and relevant medical and device
therapies.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device
company focused on commercializing the Aquadex FlexFlow® system for
aquapheresis therapy. The Aquadex FlexFlow system is
indicated for temporary (up to eight hours) ultrafiltration
treatment of patients with fluid overload who have failed diuretic
therapy and extended (longer than 8 hours) ultrafiltration
treatment of patients with fluid overload who have failed diuretic
therapy and require hospitalization. All treatments must be
administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies. The company's mission is to
predict, measure, and control patient fluid balance through
science, collaboration, and innovative medical technology.
CHF Solutions is a Delaware corporation headquartered
in Minneapolis, Minnesota with wholly owned subsidiaries
in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, the company’s plans for the Society of Thoracic
Surgeons Annual Meeting. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our ability to execute on
our commercial strategy, the possibility that we may be unable to
raise sufficient funds necessary for our anticipated operations,
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak
only as of the date when made. CHF Solutions does not
assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACTS:
INVESTORS: Claudia Napal Drayton Chief
Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com
-or- Bret Shapiro Managing Partner CORE IR 516-222-2560
brets@coreir.com www.coreir.com
MEDIA Jules Abraham JQA Partners, Inc.
917-885-7378 jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024